Effects of Hemoglobin-Based Oxygen Carriers on Blood Coagulation
Source abstract
Abstract
For many decades, Hemoglobin-based oxygen carriers (HBOCs) have been central in the development of resuscitation agents that might provide oxygen delivery in addition to simple volume expansion. Since 80% of the world population lives in areas where fresh blood products are not available, the application of these new solutions may prove to be highly beneficial (Kim and Greenburg 2006). Many improvements have been made to earlier generation HBOCs, but various concerns still remain, including coagulopathy, nitric oxide scavenging, platelet interference and decreased calcium concentration secondary to volume expansion (Jahr et al. 2013). This review will summarize the current challenges faced in developing HBOCs that may be used clinically, in order to guide future research efforts in the field.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · High Altitude and Hypoxia
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Suite 3325, Los Angeles, CA 90095, USA
Department of Biology, College of Arts and Sciences, Syracuse University, Syracuse, NY 13244, USA
School of Medicine, St. George's University, Grenada, West Indies
References (34)
Show source-provided references
1. Toward 21st century blood component replacement therapeutics: Artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others10.1080/10731190600973725 ↗
2. Jahr, J.S., Chung, M., Anvarhosseini, A., and Kim, H.W. (2013). Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics, Springer Heidelberg.
3. Facts and Figures. Available online:http://www.americasblood.org/about-blood/facts-figures.aspx.
4. Estimating the cost of blood: Past, present, and future directions10.1016/j.bpa.2007.01.002 ↗
5. Immunomodulation and blood transfusion10.1097/00045391-200209000-00005 ↗
6. Transfusion-related acute lung injury: A clinical review10.1016/S0140-6736(12)62197-7 ↗
7. Scientific aspects of supplying blood to distant military theaters10.1097/MOH.0b013e3282ef477f ↗
8. (2007). TEG 5000 User’s Manual, Haemoscope Inc.
9. Tem Innovations GmbH Munich. Available online:http://www.sfgh-poct.org/wp-content/uploads/2013/02/ROTEM-delta-US-Operating-Manual-Part-12.pdf.
10. Clinical application of the PFA-10010.1097/00062752-200209000-00004 ↗
11. Kottke-Marchant, K. (2008). An Algorithmic Approach to Hemostasis Testing, College of American Pathologists.
12. Coagulation patterns following hemoglobin-based oxygen carrier resuscitation in severe uncontrolled hemorrhagic shock in swine10.1111/j.1365-3148.2006.00678.x ↗
13. Does HBOC-201 (Hemopure) affect platelet function in orthopedic surgery: A single-siteanalysis from amulticenter study?10.1097/MJT.0b013e3181a2b08d ↗
14. The in vitro effects of crystalloids and colloid on coagulation10.1046/j.1365-2044.2002.02782_1.x ↗
15. Coagulation dynamics after hemodilution with polyhemoglobin
16. Low-and medium-molecular-weight hydroxyethyl starches: Comparison of their effect on blood and coagulation10.1097/00000542-200011000-00016 ↗
17. The effect of hemopure on coagulation in clinically relevant concentrations10.1213/01.ANE.0000136477.46472.EB ↗
18. Effects of bovine polymerized hemoglobin on coagulation in controlled hemorrhagic shock in swine10.1097/01.shk.0000170354.18437.2f ↗
19. Hemolink, an o-raffinose cross-linked haemoglobin-based oxygen carrier, does not affect activation and function of human platelets in whole blood in vitro10.1046/j.1365-2141.2003.04068.x ↗
20. O-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits10.1182/blood.V96.10.3630 ↗
21. HBOC-201 as an alternativeto blood transfusion: Efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery
22. Williams, J.P., Tseuda, K., Vandermeersch, E., Bourke, D.L., and Jahr, J.S. (2002, January 26–29). Transfusion requirements in Phase III study of HBOC-201 (Hemopure®, Hemoglobin gutamer-250, bovine), a bovinehemoglobin based blood substitute. Presented at the American Association of Blood Banks: 55th Annual Meeting, Orlando, FL, USA.
23. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch10.1046/j.1537-2995.2002.00003.x ↗
24. Hemostatic changes in patients receiving hydroxyethyl starch: The influence of ABO blood group10.1097/00000539-200106000-00007 ↗
25. Binding of hydroxyethyl starch molecules to the platelet surface10.1213/01.ANE.0000073353.31894.BE ↗
26. Does Hextend impair coagulation compared to 6% hetastarch? An ex vivo thromboelastography study10.1097/MJT.0b013e31815aec71 ↗
27. Methemoglobin effects on coagulation: A dose-response study with HBOC-200 (Oxyglobin) in a thrombelastogram model10.1053/j.jvca.2008.06.006 ↗
28. Does OxyVita, a new-generation hemoglobin-based oxygen carrier, or oxyglobin, acutely interfere with coagulation compared with normal saline or 6% hetastarch? An ex vivo thrombelastography study10.1053/j.jvca.2007.02.016 ↗
29. Biophysical properties and oxygenation potential of high molecular weight polymerized human hemoglobins maintained in the tense and relaxed quaternary states10.1089/ten.tea.2010.0353 ↗
30. Oxygen carriers (“blood substitutes”) raison d’Etre, chemistry, and some physiology blut ist ein ganz besondrer Saft 110.1021/cr970143c ↗
31. Oxygen therapeutics: Can we tame haemoglobin?10.1038/nrd1307 ↗
32. Blood substitutes10.1016/S0169-409X(99)00045-9 ↗
33. Current status of blood substitute research: Towards a new paradigm10.1046/j.1365-2796.2003.01150.x ↗
34. Polymerization of hemoglobins in Arctic fish: Lycodes reticulatus and Gadus morhua10.1002/iub.450 ↗